Long-Term Stability of Alzheimer's Disease Biomarker Proteins in Cerebrospinal Fluid

2011 ◽  
Vol 26 (2) ◽  
pp. 255-262 ◽  
Author(s):  
Carola G. Schipke ◽  
Frank Jessen ◽  
Stefan Teipel ◽  
Christian Luckhaus ◽  
Jens Wiltfang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Term Stability ◽  
Long Term Stability ◽  
Disease Biomarker

scholarly journals Effects of Risperidone and Galantamine Treatment on Alzheimer’s Disease Biomarker Levels in Cerebrospinal Fluid

2017 ◽  
Vol 57 (2) ◽  
pp. 387-393 ◽  
Author(s):  
Victor Bloniecki ◽  
Dag Aarsland ◽  
Kaj Blennow ◽  
Jeffrey Cummings ◽  
Farshad Falahati ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Disease Biomarker

scholarly journals Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Peter Wostyn ◽  
Debby Van Dam ◽  
Kurt Audenaert ◽  
Peter Paul De Deyn
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Late Onset ◽  
Senile Plaques ◽  
Protective Effects ◽  
Caffeine Consumption ◽  
Neuroprotective Effects ◽  
Csf Production

Alzheimer's disease (AD), the most common type of dementia among older people, is characterized by the accumulation of β-amyloid (Aβ) senile plaques and neurofibrillary tangles composed of hyperphosphorylated tau in the brain. Despite major advances in understanding the molecular etiology of the disease, progress in the clinical treatment of AD patients has been extremely limited. Therefore, new and more effective therapeutic approaches are needed. Accumulating evidence from human and animal studies suggests that the long-term consumption of caffeine, the most commonly used psychoactive drug in the world, may be protective against AD. The mechanisms underlying the suggested beneficial effect of caffeine against AD remain to be elucidated. In recent studies, several potential neuroprotective effects of caffeine have been proposed. Interestingly, a recent study in rats showed that the long-term consumption of caffeine increased cerebrospinal fluid (CSF) production, associated with the increased expression of Na+-K+ATPase and increased cerebral blood flow. Compromised function of the choroid plexus and defective CSF production and turnover, with diminished clearance of Aβ, may be one mechanism implicated in the pathogenesis of late-onset AD. If reduced CSF turnover is a risk factor for AD, then therapeutic strategies to improve CSF flow are reasonable. In this paper, we hypothesize that long-term caffeine consumption could exert protective effects against AD at least in part by facilitating CSF production, turnover, and clearance. Further, we propose a preclinical experimental design allowing evaluation of this hypothesis.

P1-010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker?

2015 ◽  
Vol 11 (7S_Part_7) ◽  
pp. P340-P340
Author(s):  
Henrietta Wellington ◽  
Ulrika Törnqvist ◽  
Erik Portelius ◽  
Ross W. Paterson ◽  
Nadia K. Magdalinou ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Neurodegenerative Diseases ◽  
Synaptic Protein ◽  
Disease Biomarker

scholarly journals Alzheimer's Disease Biomarker Profile in Cerebrospinal Fluid of Individuals with Immune-Mediated Encephalitis

2016 ◽  
Vol 64 (9) ◽  
pp. e29-e31
Author(s):  
Marcos Fernandez Suarez ◽  
Ezequiel I. Surace ◽  
Miguel Riudavets ◽  
Martin Nogues ◽  
Silvia Vazquez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Disease Biomarker ◽  
Immune Mediated

scholarly journals TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

2021 ◽  
Author(s):  
Shengjun Hong ◽  
Valerija Dobricic ◽  
Olena Ohlei ◽  
Isabelle Bos ◽  
Stephanie J. B. Vos ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Genetic Determinants ◽  
Disease Biomarker

Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study

2020 ◽  
Vol 93 ◽  
pp. 97.e1-97.e7 ◽  
Author(s):  
Bryant Lim ◽  
Sigrid Botne Sando ◽  
Gøril Rolfseng Grøntvedt ◽  
Geir Bråthen ◽  
Eleftherios P. Diamandis
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Follow Up Study ◽  
Neuronal Pentraxin
Sign in / Sign up

Export Citation Format

Share Document